Status:
COMPLETED
The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors
Lead Sponsor:
Istituto Clinico Humanitas
Conditions:
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Over the last decade, improvements in the investigators' understanding of the molecular basis of cancer have led to the clinical development of protein kinase inhibitors, which target pivotal molecule...
Detailed Description
This is a dual-agent, prospective, open-label, multi-centric, phase I trial of combination of Lapatinib and Sorafenib in patients with locally advanced, recurrent or metastatic solid tumors. This tria...
Eligibility Criteria
Inclusion
- Patients with locally advanced, recurrent or metastatic histologically confirmed malignancy refractory to available standard treatment
Exclusion
- Prior treatment with Lapatinib, Sorafenib or any agents targeting EGFR (other than trastuzumab), Raf, VEGF, or VEGFR
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00984425
Start Date
September 1 2009
End Date
August 1 2013
Last Update
December 2 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinco Humanitas
Rozzano, Milano, Italy, 20089